Downregulation of HIF-1 expression level can inhibit the proliferation of liver cancer cells, and knockdown of AKT expression can inhibit the proliferation of liver cancer cells, reduce the expression level of HIF-1, and synergize with the low expression of HIF-1 to inhibit the proliferation of liver cancer cells [17], and metuximab combined with TACE sequential surgery in the treatment of primary liver cancer can inhibit the high expression of VEGF and AFP, improve survival rate, reduce the rate of metastasis and recurrence, and improve the quality of life [18]. The gene discussed is HIF1A; the disease is liver cancer.